F-18 fluorodeoxyglucose: its potential in differentiating between stress fracture and neoplasia.
F-18 fluorodeoxyglucose (FDG) accumulates into regions of enhanced glucose uptake and metabolism such as the brain, heart, and malignant tumors. The clinical usefulness of this positron-emitting radiopharmaceutical is illustrated in a case where the clinical picture and CT indicated a malignant bone lesion in the clavicle. Histologically a stress fracture was found secondary to chronic strain on the clavicle. On follow-up the lesion's course was benign. Planar imaging with F-18 FDG was performed twice during follow-up, and on both occasions there was no accumulation of radioactivity over the suspicious area, indicating normal glucose consumption. This case demonstrates the differential diagnostic potential of F-18 FDG and shows that clinically useful information may be obtained without a position emission tomograph.
Paul
R
R
Department of Radiotherapy, University Central Hospital, Turku, Finland.
Ahonen
A
A
Virtama
P
P
Aho
A
A
Ekfors
T
T
D000293:Adolescent; D001859:Bone Neoplasms / Q000000981:diagnostic imaging*; D002968:Clavicle / Q000293:injuries*; D003837:Deoxy Sugars; D003847:Deoxyglucose / Q000031:analogs & derivatives; D003937:Diagnosis, Differential; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D015775:Fractures, Stress / Q000000981:diagnostic imaging*; D006801:Humans; D011877:Radionuclide Imaging
D003837:Deoxy Sugars; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose